Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Reduced by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 44,021 shares of the biopharmaceutical company’s stock after selling 2,100 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Halozyme Therapeutics were worth $1,627,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Principal Securities Inc. purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at about $34,000. First Horizon Advisors Inc. lifted its stake in Halozyme Therapeutics by 24.5% during the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 293 shares in the last quarter. Parkside Financial Bank & Trust purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at about $64,000. Headlands Technologies LLC lifted its stake in Halozyme Therapeutics by 1,068.2% during the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 1,613 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in Halozyme Therapeutics by 22.4% during the fourth quarter. Quadrant Capital Group LLC now owns 3,414 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 624 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. TD Cowen assumed coverage on shares of Halozyme Therapeutics in a research report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, June 4th. JMP Securities reduced their price target on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 8th. Benchmark reissued a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, April 16th. Finally, Piper Sandler lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $48.00 to $51.00 in a research report on Friday, June 7th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $54.13.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $51.55 on Friday. The firm has a market cap of $6.56 billion, a PE ratio of 21.30, a PEG ratio of 0.51 and a beta of 1.28. The firm’s 50 day moving average price is $43.93 and its 200 day moving average price is $40.05. The company has a debt-to-equity ratio of 8.44, a quick ratio of 5.36 and a current ratio of 6.64. Halozyme Therapeutics, Inc. has a twelve month low of $32.83 and a twelve month high of $53.00.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The company had revenue of $195.88 million for the quarter, compared to the consensus estimate of $201.72 million. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total transaction of $384,900.00. Following the transaction, the senior vice president now owns 168,176 shares in the company, valued at $6,473,094.24. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 30,000 shares of company stock worth $1,338,800 over the last 90 days. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.